Cardiovascular Pharmacogenomics: Current Status and Future Directions—Report of a National Heart, Lung, and Blood Institute Working Group
Open Access
- 12 April 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Heart Association
- Vol. 1 (2), e000034
- https://doi.org/10.1161/jaha.111.000554
Abstract
Background Patients with bicuspid aortic valve (BAV) have an increased risk of developing ascending aortic aneurysm. In the present study, collagen homeostasis in nondilated and dilated aorta segments from patients with BAV was studied, with normal and dilated aortas from tricuspid aortic valve (TAV) patients as reference. Methods and Results Ascending aortas from 56 patients were used for biochemical and morphological analyses of collagen. mRNA expression was analyzed in 109 patients. Collagen turnover rates were similar in nondilated and dilated aortas of BAV patients, showing that aneurysmal formation in BAV is, in contrast to TAV, not associated with an increased collagen turnover. However, BAV in general was associated with an increased aortic collagen turnover compared with nondilated aortas of TAV patients. Importantly, the ratio of hydroxylysyl pyridinoline (HP) to lysyl pyridinoline (LP), 2 distinct forms of collagen cross‐linking, was lower in dilated aortas from patients with BAV, which suggests that BAV is associated with a defect in the posttranslational collagen modification. This suggests a deficiency at the level of lysyl hydroxylase (PLOD1), which was confirmed by mRNA and protein analyses that showed reduced PLOD1 expression but normal lysyl oxidase expression in dilated aortas from patients with BAV. This suggests that impaired collagen cross‐linking in BAV patients may be attributed to changes in the expression and/or activity of PLOD1. Conclusions Our results demonstrate an impaired biosynthesis and posttranslational modification of collagen in aortas of patients with BAV, which may explain the increased aortic aneurysm formation in BAV patients.This publication has 37 references indexed in Scilit:
- Warfarin Genotyping Reduces Hospitalization Rates: Results From the MM-WES (Medco-Mayo Warfarin Effectiveness Study)Journal of the American College of Cardiology, 2010
- Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patientsPharmacogenetics and Genomics, 2009
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataThe New England Journal of Medicine, 2009
- The largest prospective warfarin-treated cohort supports genetic forecastingBlood, 2009
- Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial FibrillationAnnals of Internal Medicine, 2009
- CYP4F2 genetic variant alters required warfarin doseBlood, 2008
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology & Therapeutics, 2008
- Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral AnticoagulationCirculation, 2007
- CYP2C9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled StudyClinical Pharmacology & Therapeutics, 2007
- Association of warfarin dose with genes involved in its action and metabolismHuman Genetics, 2006